/
DTIL
$7.92+$0.63 (+8.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$188.1M
26M shares
52-week range
$3.53 – $8.82
83% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.98%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-371.88
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.8M |
| Gross profit | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $31.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.0% |
| R&D | $45.1M | $82.4M | $98.1M | $115.2M | $46.1M | $53.4M | $59.6M | $54.2M |
| Operating income | −$47.9M | −$87.2M | −$109.8M | −$39.4M | −$62.3M | −$43.7M | −$26.2M | −$52.1M |
| EBITDA | −$43.7M | −$87.4M | −$99.2M | −$20.3M | −$62.8M | −$32.0M | $13.5M | −$42.4M |
| Net income | −$46.0M | −$92.9M | −$109.0M | −$30.6M | −$111.6M | −$61.3M | $7.2M | −$46.6M |
| Net margin | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -136.0% |
| EPS (diluted) | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.04 | -3.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-2.81 | $-3.79–$-1.82 | 3 |
| 2027 | $14M | $-2.31 | $-2.72–$-1.88 | 3 |
| 2028 | $18M | $-2.06 | $-2.96–$-1.44 | 4 |
| 2029 | $25M | $-2.12 | $-3.73–$-0.88 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
www.precisionbiosciences.com- Employees
- 66
- IPO / List date
- Mar 28, 2019
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds DTIL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 223,177 | $1.2M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-14 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded DTIL yet.
